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Simple Summary: The presence of polymorphic gene variants in the human genome provides
extensive genetic (and eventually phenotypic) variation affecting both normal physiological
mechanisms and cancer pathogenesis. Functional genetic polymorphisms might have predictive
and/or prognostic value in lung cancer, opening novel opportunities to improve prediction and
guide clinical reasoning and therapeutics in lung cancer patients. Recent knowledge pinpoints a
pleiotropic role for renin-angiotensin system, particularly in the lung and mainly through locally
regulated alternative molecules and secondary pathways. Dysregulation of this system play a role in
cell proliferation, hypoxia and angiogenesis, which processes are involved in lung cancer progression.
Here we suggest that polymorphic variants in genes coding for renin-angiotensin system might play
a role in Non-Small Cell Lung Cancer progression.
Abstract: Introduction: The renin–angiotensin system (RAS) is involved in cell proliferation,
immunoinflammatory response, hypoxia and angiogenesis, which are critical biological processes in
Cancers 2020, 12, 3834; doi:10.3390/cancers12123834 www.mdpi.com/journal/cancers
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lung cancer. Our aim was to study the association of putatively functional genetic polymorphisms
in genes coding for proteins involved in RAS, hypoxia and angiogenesis with non-small cell lung
cancer (NSCLC) prognosis. Methods: Genotyping of 52 germline variants from genes of the RAS and
hypoxic/angiogenic factors/receptors was performed using MassARRAY iPLEX Gold in a retrospective
cohort (n = 167) of advanced NSCLC patients. Validation of the resulting genetic markers was
conducted in an independent group (n = 190), matched by clinicopathological characteristics. Results:
Multivariate analysis on the discovery set revealed that MME rs701109 C carriers were protected
from disease progression in comparison with homozygous T (hazard ratio (HR) = 0.5, 95% confidence
interval (CI) = 0.2–0.8, p = 0.010). Homozygous A and T genotypes for KDR rs1870377 were at
increased risk for disease progression and death compared to heterozygous (HR = 1.7, 95% CI = 1.2–2.5,
p = 0.005 and HR = 2.1, 95% CI = 1.2–3.4, p = 0.006, respectively). Carriers of homozygous genotypes
for ACE2 rs908004 presented increased risk for disease progression, only in the subgroup of patients
without tumour actionable driver mutations (HR = 2.9, 95% CI = 1.3–6.3, p = 0.010). Importantly,
the association of homozygous genotypes in MME rs701109 with risk for disease progression was
confirmed after multivariate analysis in the validation set. Conclusion: This study provides evidence
that MME polymorphism, which encodes neprilysin, may modulate progression-free survival in
advanced NSCLC. Present genetic variation findings will foster basic, translational, and clinical
research on their role in NSCLC.
Keywords: genetic polymorphisms; lung cancer; renin–angiotensin; hypoxia; angiogenesis
1. Introduction
Lung cancer is one of the most common malignancies worldwide and the most common cause of
cancer death, with over one million people diagnosed worldwide each year [1].
The renin–angiotensin system (RAS) is an established primary regulator of blood pressure,
homeostasis, and natriuresis [2]. Recent evidences indicate that angiotensin peptides might have
a role in tumour cell proliferation, inflammation, immune surveillance, hypoxia and angiogenesis,
which have been recognized as hallmarks of cancer, and thereby actively participating in lung
tumour microenvironment regulation [3,4]. The enzymatic cascade leading to Angiotensin II
(Ang II) production includes renin, which cleaves angiotensinogen (AGT) to form angiotensin I
(Ang I). Angiotensin-converting enzyme (ACE) cleaves Ang I to produce Ang II [2]. The chymase,
which might catalyse the conversion from Ang I to Ang II, has been associated with activation of
proliferation, adhesion, regulation of E-cadherin expression, and modulation of the immunosuppressive
microenvironment in lung carcinoma [5,6]. Angiotensin-(1-7) (Ang-(1-7)) has opposite effects to Ang II
through binding to Mas receptor (MasR), and is obtained by catalysis from the enzymes ACE type 2
(ACE2) or neprilysin (NEP) [7]. On its turn, NEP has been associated with some malignancies, such as
prostate, renal and lung cancer [8].
In vitro and in vivo studies showed that activation of the ACE/Ang II/ angiotensin II
type 1 receptor (ATR1) axis promotes cancer cell proliferation, invasion, angiogenesis and
reduced immunosurveillance [9–11]. Conversely, anti-tumour effects were demonstrated for the
ACE2/Ang-(1-7)/MasR axis [12–14]. Upregulated expression of ATR1 transcripts in lung tumours
suggests that Ang II, acting upon the ATR1, plays an important role in cell growth and invasion [15],
whereas decreased expression of genes encoding for ACE2/Ang-(1–7)/MasR axis proteins in lung
tumours halt MasR signalling, which is contrary to Ang II/ATR1 [16]. Notably, clinical studies revealed
that RAS inhibitors combined with chemotherapy and Epidermal growth factor receptor (EGFR)
tyrosine kinase inhibitors prolonged progression-free survival in non-small cell lung cancer (NSCLC)
patients [17–19].
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Activity and modulation of the RAS are dependable of germline genetic variations [20],
somatic mutations [21], environmental stimulus and from hypoxic lung tumour microenvironment [22].
Additionally, the RAS is causally and consequently associated with hypoxia and angiogenesis,
considered in continuum as branches of RAS [4]. Notwithstanding, the RAS remains largely unexplored
at translational and clinical levels in cancer, particularly NSCLC. In this study, we sought to evaluate
whether functional genetic variants coding for proteins of RAS and hypoxic/angiogenic factors/receptors
have predictive and/or prognostic value in NSCLC using progression-free survival (PFS) and overall
survival (OS) as clinical endpoints.
2. Material and Methods
2.1. Study Population: Discovery and Validation Sets
This study comprised a retrospective cohort of histologically confirmed NSCLC patients (n = 167)
with clinical advanced stage at diagnosis (IIIA-IVB), between 2012 and 2018. Participants were
consecutively recruited during routine follow-up visit, since August 2017 to October 2018 from
Coimbra University Hospital (discovery set). The validation set comprised an independent cohort of
NSCLC patients (n = 190) selected from the Lung Biobank Heidelberg, member of the Biomaterialbank
Heidelberg (BMBH) and the biobank platform of the German Centre for Lung Research (DZL).
All patients were recruited at Thoraxklinik (University Hospital of Heidelberg) between 2015–2018,
using the same matched clinical and pathological criteria from the discovery set.
Histolopathogical diagnoses in both sets were made by experienced pathologists following
the 2009 and 2015 WHO classification criteria for lung cancer, accordingly to the year of patient’s
diagnosis. The existence of concomitant primary tumours in another organ was considered as
exclusion criteria for both cohorts. Clinical data was retrieved from clinical charts on pathological
background, previous medication, Eastern Cooperative Oncology Group performance status (ECOG
PS) at diagnosis, TNM staging according to 8th classification, tumour mutational status, type of cancer
treatment, disease progression/death by clinical authors. Informed consent was obtained from each
participant and all procedures are in agreement with Helsinki Declaration.
In the discovery set, somatic mutations in EGFR, ALK and ROS1 were determined using
fluorescence in situ hybridization (FISH), in patients with adenocarcinoma stage IVA-IVB, whereas for
the validation set, somatic mutations were determined through panel-based next generation sequencing
in advanced NSCLC patients [23]. In both cohorts, targeted therapies were administered to carriers of
actionable driver mutations, whereas checkpoint inhibitors were used as second-, or third-line therapy
for patients with PD-L1 expression on tumour cells below 50%.
The primary endpoint was PFS and the time-to-disease progression was calculated in months,
from the date of first line chemotherapy/target therapy, until the date of progression according to
RECIST criteria. OS was included as secondary endpoint, and the time-to-death was computed in
months from the date of first line chemotherapy/target therapy until the date of death/date of last visit.
2.2. Selection of Genetic Polymorphisms
Fifty-two single nucleotide polymorphisms (SNP) included in the present study from the genes
ACE, ACE2, AGT, AGTR1, AGTR2, MME, CMA1, MAS1, HIF1A, VEGFA, KDR, PGF and FLT1 (Table S1)
were selected from search in genomic public databases, in silico analysis and review of scientific
literature, to identify putatively functional polymorphisms [24–37]. Polymorphisms with minor allele
frequency below 1% were excluded [37].
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2.3. Genotyping
2.3.1. Discovery Set
Each patient donated a sample of blood (~4 mL) for research, collected to EDTA-Vacutainer tubes,
at the same time of blood collection for routine analytic follow-up. The collected blood was centrifuged
to obtain the buffy coat, which was used to isolate and purify DNA by the EZ1 DNA Blood kit in the
EZ1 BioRobot (QIAgen, Hilden, Germany). The selected SNPs were genotyped using the Sequenom
Mass ARRAY matrix-assisted laser desorption/ionization time-of-flight mass spectrometry platform
(Sequenom, San Diego, CA, USA). Primers were designed using semi-automated Assay Design 3.1
Software (Sequenom). The global genotyping success rate was 99.85% with 100% replication agreement
among one third of the samples.
2.3.2. Validation Set
Buffy coat samples were provided by Lung Biobank Heidelberg from patients diagnosed with
advanced NSCLC (clinical stage IIIA-IVB). DNA extraction and purification were conducted using
the FlexiGene DNA Kit (QIAgen). The resulting genetic polymorphisms, associated with disease
progression or overall survival from multivariate analysis in the discovery set, were genotyped in the
validation set using Real-Time PCR. Allelic discrimination was obtained using TaqMan SNP genotyping
assays: ACE2 rs908004 (Assay ID: C___8816953_20), MME rs701109 (Assay ID: C____964850_10) and
KDR rs1870377 (Assay ID: C__11895315_20) (all from Thermo Fisher Scientific, Waltham, MA, USA).
Quality control included non-template controls in all runs and blind replicate assessment in 5% of the
samples. Genotype was assigned for 96.3% of all samples tested.
2.4. Statistical Analysis
Descriptives were depicted as average ± standard deviation or median (interquartile range)
according to departure from normality (Shapiro-Wilk test). Central tendency data was compared
using the t-test, Mann-Whitney or Kruskal-Wallis tests according to normality and stratification of
independent variables. Categorical variables were expressed as frequency (percentage) and proportions
tested using the chi-square test. The difference in median months of PFS and OS from both cohorts
was calculated through Kaplan-Meier curve with log rank test.
Four genetic models were considered in this study: each SNP was stratified according to the wild
type allele into additive (“AA” genotype versus “Aa” versus “aa”), dominant (“AA” genotype versus
“Aa” and “aa” genotypes), recessive (“Aa” and “AA” versus “aa” genotype) and heterosis (“Aa” versus
“AA” and “aa” genotypes). The wild-type allele for each SNP was designated in agreement with
Ensembl [37]. Empirical analyses were conducted on clinicopathological and genetic variables to test
the association with time-to-outcome, using Cox regression analyses. After univariate analyses, p < 0.10
and an effect > 30% in hazard ratio (HR) were used as criteria for inclusion in a multivariated Cox with
stepwise regression model. Genetic models with under-represented variant genotype (n < 4) were
excluded from the multivariate analysis, and only the genetic model with the highest likelihood ratio
for each SNP was included in the multivariate model to avoid collinearity. The resulting multivariated
model was further tested with bootstrapping (MonteCarlo simulations, 1000 iterations), to elect the
resulting relevant markers to be tested in the validation set. To investigate the possible predictive
value of each SNP in treatment response for first line therapy, and time-to-progression or time-to-death,
exploratory analyses were conducted examining the effect of genotype in a subgroup of patients
treated with first line platinum doublet chemotherapy and in another subgroup of wild-type EGFR
(epidermal growth factor receptor) patients, using the same survival analysis methods. Sample size,
power, effect size and number of events for survival analyses (assuming alpha = 0.05 and power > 0.8)
were estimated in both cohorts. Statistical analyses were performed on STATA software version 16.0
(StataCorp, College Station, TX, USA).
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2.5. Ethics Approval
This project has been reviewed and approved by Coimbra University Hospital’s Ethical Committee
(ref. no. 0111/CES) and by the Portuguese National Committee for data protection (ref. no. 2588/2017).
The biobank protocol of Lungbiobank Heidelberg was approved by the ethics committee of the
University of Heidelberg (S-270/2001).
3. Results
The clinicopathological characteristics of participating subjects from discovery and validation sets
are described in Table 1. Regarding mutational status from discovery set (n = 167), we observed that
10.8% of patients (n = 18) had EGFR mutation (exon 19 deletions or exon 21 mutation), whereas 3.0%
(n = 5) had rearrangements in the gene encoding anaplastic lymphocyte kinase (ALK). Mutations of
ROS1 were not detected. From the validation set (n = 190), 15.3% (n = 29) of NSCLC patients had EGFR
mutation (exon 19 deletions or exon 21 mutation), 13.7% (n = 26) were KRAS mutated, 4.2% (n = 8)
had EML4-ALK fusion, 2.6% (n = 5) had BRAF V600E mutation. No other targetable mutations were
identified. Concerning respiratory co-morbidities from discovery set, twenty patients (12.0%) had
moderate-severe COPD with lung emphysema and one patient (0.6%) had sarcoidosis, whereas in the
validation set there were fifty patients (26.3%) with moderate-severe COPD and lung emphysema,
and five patients (2.6%) had idiopathic pulmonary fibrosis.
Table 1. Patient′s clinical characteristics.
Clinical Variables. Discovery Set (N = 167) Validation Set (N = 190) p
Gender, n
Males 123 (73.7%) 133 (70.0%)
Females 44 (26.3%) 57 (30.0%) 0.445 *
Age (years)
Median (IQR) 64.0 (58.0–72.0) 65.0 (58.0–73.0) 0.773 **
Smoking Status, n (%)
Never smokers 31 (27.7%) 20 (10.5%)
Previously smokers 68 (60.7%) 97 (51.1%)
Smokers 13 (11.6%) 73 (38.4%) <0.0001 *
Hypertension, n (%)
Yes 67 (48.6%) 91 (47.9%)
No 71 (51.4%) 99 (52.1%) 0.911 *
Anti-hypertension drugs, n (%)
No 86 (65.2%) 126 (67.0%)
iACE/ARB 46 (34.8%) 62 (33.0%) 0.728 *
ECOG PS, n (%)
0–2 163 (97.6%) 188 (98.9%)
>2 4 (2.4%) 2 (1.1%) 0.153 *
Histology, n (%)
Adenocarcinoma 116 (69.5%) 126 (66.3%)
Squamous cell carcinoma 42 (25.1%) 62 (32.6%)
Adeno + Squamous cell 9 (5.4%) 2 (1.1%) 0.066 *
cTNM Stage, n (%)
IIIA 20 (12.0%) 27 (14.2%)
IIIB 32 (19.2%) 36 (18.9%)
IIIC 21 (12.6%) 18 (9.5%)
IVA 65 (38.9%) 66 (34.7%)
IVB 29 (17.4%) 43 (22.6%) 0.597 *
Treatment modality, n (%)
Surgery + ChT 12 (7.2%) 0 (0.0%)
ChT + RT 31 (18.6%) 81 (42.6%)
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Table 1. Cont.
ChT 124 (74.3%) 109 (57.4%) <0.0001 *
First-line treatment, n (%)
Platinum based ChT 145 (86.8%) 155 (81.6%)
TKI 22 (12.8%) 35 (18.4%) 0.194 *
PFS (months)
Median, 95% CI 7.5 (6.1–9.0) 8.1 (6.8–9.4) 0.415 ***
OS (months)
median, 95% CI 30.0 (16.9–43.2) 20.6 (16.3–24.9) 0.036 ***
IQR—interquartil range; iACE—inhibitors of angiotensin-converting enzyme, ARB—AngiotensinII receptor blocker,
ECOG PS—Eastern cooperative Oncology Group Performance Status; ChT—chemotherapy; RT—radiotherapy;
TKI—tyrosine kinase inhibitors; 95% CI—confidence interval. PFS—progression-free survival, OS—overall survival.
* Pearson Chi Square test. ** Mann-Whitney U test. *** Kaplan Meier curve with log rank test.
The description of clinical-pathological variables is depicted in Table S2 with report of univariate
analyses for PFS and OS. Genotypic distribution of functional SNPs in genes of the renin-angiotensin
pathway, hypoxic and angiogenic factors using additive, dominant, recessive and heterosis models
from discovery set are described in Table S3, together with hazard and survival univariate analyses.
The univariate analysis showed that carriers of allele T (n = 112, 67.1%) for the SNP rs4316 in ACE gene
had a significant protection to disease progression (Hazard ratio (HR) = 0.6, 95% confidence interval
(CI) (0.4–0.9), p = 0.011). Homozygous GG/CC for ACE2 rs908004 (n = 151, 90.4%) had increased risk
for disease progression (HR = 2.1, 95% CI (1.1–3.9), p = 0.021). Another SNP from MME gene that
encodes for neprilysin, showed a tendency between the dominant genetic model of MME rs701109 and
PFS, having the heterozygous CT and homozygous CC protection to disease progression (HR = 0.6,
95% CI (0.3–1.0), p = 0.064). Univariate analysis also showed a significant association between the
functional genetic variant of VEGFA rs25648 with time to tumour progression, being the homozygous
C and T (n = 127, 78.9%) associated with worse prognosis (HR = 1.7, 95% CI (1.1–2.6), p = 0.030).
The data showed a tendency between the heterosis genetic model of KDR rs1870377 and time to tumour
progression, having the homozygous A and T increased risk to disease progression (HR = 1.4, 95% CI
(1.0–2.0), p = 0.054) and to death (HR = 1.7, 95% CI (1.0–2.7), p = 0.034).
Multivariate analysis included the relevant variables (both clinical-pathological and genetic) from
univariate empirical analysis (Table 2, Table 3). The C carriers (n = 149, 89.7%) for MME rs701109 had
significantly decreased risk for disease progression than homozygotes T (n = 17, 10.3%), regardless of
relevant clinical-pathological variables, namely tumour size, distant metastasis, type of systemic
therapy, treatment modality or from other relevant SNPs (Table 2). Homozygous A and T for KDR
rs1870377 (n = 99, 59.3%) had significantly lesser PFS and OS compared to heterozygous (n = 68,
40.7%), regardless of relevant clinical and pathological variables (Tables 2 and 3). Notably, these results
maintained its significance after boostrapping, as a statistical method for internal validation.
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T3-4 1.7 (1.3–2.2) <0.0001 * 1.7 (1.3–2.3) <0.0001 *
Distant metastasis
No Referent Referent
Yes 1.7 (1.2–2.4) 0.005 1.7 (1.1–2.5) 0.009
Type of Therapy
Surgery + ChT Referent Referent
ChT













TC/CC 0.5 (0.3–0.9) 0.018 0.5 (0.2–0.9) 0.030
Analyses were conducted using stepwise Cox regression, followed by Bootstrap analysis (Montecarlo simulations
with 1000 iterations). HR, hazard ratio, 95% CI, confident interval, ChT, chemotherapy, RT, radiotherapy, TKi,
tyrosine kinase inhibitors. * p trend value.
Table 3. Multivariate analysis of relevant variables for overall survival (OS) in the discovery set











T3-4 1.5 (1.1–2.2) 0.018 * 1.5 (1.0–2.2) 0.066 *
Distant metastasis
No Referent Referent
Yes 2.5 (1.5–4.3) 0.001 2.6 (1.5–4.5) 0.001
Age median
≤64.0 Referent Referent




TT/AA 2.1 (1.2–3.4) 0.006 2.0 (1.2–3.3) 0.012
HR, hazard ratio, 95% CI, confident interval. * p trend value.
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Exploratory subgroup analyses were conducted among NSCLC patients from discovery set that
included only patients under first line platinum-based doublet chemotherapy without actionable driver
mutations (n = 145) or EGFR wild-type (n = 149). Within the MME (rs701109) and KDR (rs1870377)
polymorphisms, we found evidence for an independent effect at PFS and OS respectively, across all
subgroups. Notably, CT and CC patients for MME (rs701109) under first line platinum-based doublet
chemotherapy or EGFR wild-type had protection for disease progression (HR = 0.4, 95% CI (0.2–0.7),
p = 0.005 and HR = 0.4, 95% CI (0.2–0.8), p = 0.006, respectively). Homozygous A and T for KDR
rs1870377 had increased risk to death also in patients under first line platinum doublet chemotherapy
or EGFR wild-type (HR = 1.9, 95% CI (1.1–3.2), p = 0.019 and HR = 2.0, 95% CI (1.2–3.4), p = 0.011,
respectively). Moreover, from the multivariate analysis conducted in the subgroup of patients
treated with first line platinum-based doublet chemotherapy without actionable driver mutations
(n = 145), we also found that homozygous for ACE2 rs908004 had increased risk for disease progression,
regardless of relevant clinical-pathological covariates (HR = 2.9, 95% CI (1.3–6.3), p = 0.010).
The validation set included an independent matched cohort of NSCLC patients (Table 1) to
validate the resulting genetic SNPs from the discovery set. Results from univariate analysis of
clinicopathological variables in association with PFS and OS are described in Table S4. The genotype
distribution and univariate analysis according to additive, dominant, recessive or heterosis models of
MME rs701109, KDR rs1870377 and ACE2 rs908004 for hazard and survival analysis are depicted in
Table S5. The genetic distribution of genotypes in MME rs701109, KDR rs1870377 and ACE2 rs908004
are similar among discovery and validation sets (p = 0.204, p = 0.846 and p = 0.251, respectively)
(Pearson Chi-square test).
The multivariate model for PFS in the validation cohort is presented in Table 4. Homozygous
(n = 102, 53.9%) for MME rs701109 had significantly increased risk to disease progression compared to
CT genotype (n = 87, 46.0%), regardless of histology, type of systemic therapy or treatment modality
(chemotherapy or chemo and radiotherapy). There was no significant effect on overall survival for
MME rs701109, KDR rs1870377 and ACE2 rs908004.
Table 4. Multivariate analysis of relevant variables for disease progression using stepwise Cox






HR (95%CI) p HR (95%CI) p
Histology
Adenocarcinoma Referent Referent
Squamous cell 1.7 (1.2–2.4) 0.003 ** 1.7 (1.2–2.5) 0.003 **
Other * - -
Type of Therapy
ChT Referent Referent









TT/CC 1.6 (1.2–2.3) 0.005 1.6 (1.1–2.4) 0.007
PFS—progression-free survival, HR—hazard ratio, 95% CI—confident interval, ChT—chemotherapy,
RT—radiotherapy, TKi—inhibitors of tyrosine kinase. * Adenocarcinoma+squamous cell. ** p trend value.
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Subgroup analyses were also conducted in this set, for first line platinum-based doublet
chemotherapy (n = 155) and EGFR wild-type patients (n = 161). The MME rs701109 polymorphism
was associated with PFS only in the subgroup of patients with wild-type EGFR, being the homozygous
at increased risk to disease progression (HR = 1.7, 95% CI (1.1–2.5), p = 0.009).
4. Discussion
The work developed here sought to test the hypothesis that variants in genes coding for the
renin–angiotensin system and for interacting hypoxia/angiogenesis key molecules might have predictive
and prognostic value, respectively for NSCLC progression and survival. SNPs are the most common
type of polymorphisms, accounting for 90% of genetic variations [38]. Nucleotide substitution,
according to its location in germline DNA, may elicit functional modifications, ultimately at protein
level, contributing to inter-individual variability, and correlating with relevant phenotypic alterations.
The association between genetic polymorphisms and cancer susceptibility, progression, aggressiveness
and death has been thoroughly described in the literature [38].
RAS was first discovered and related with the physiological regulation of systemic arterial pressure
and involved in hypertension pathogenesis [39]. As a gatekeeper system, RAS is responsible for
more than one function, including cell cycle regulation, inflammation, angiogenesis and fibrosis [3].
The capillary blood vessels in the lung are one of the major sites of ACE expression and Ang II
production in the human body [40]. In fact, the increased ACE expression observed in several
interstitial lung diseases supports pulmonary RAS and establishes a putative role for Ang II in the
response to lung injury and fibrosis [4]. A previous report showed that the G-6A polymorphism
of the AGT gene is associated with increased angiotensin production and idiopathic pulmonary
fibrosis progression [41], which is associated with increased risk of lung cancer [42]. Furthermore,
the insertion/deletion (I/D) polymorphism of ACE gene has been linked to the pathogenesis and
progression of human cancers [43,44] and the lowest serum ACE levels were correlated with poorer
prognosis and higher relapse rates in lung cancer [15]. We found that the association between ACE
rs4316 genetic variant and PFS, despite being significant in univariate, the finding was not confirmed
on multivariate analysis. It is an I/D polymorphism and is localized at intron 16 of ACE gene. This SNP
has been associated with plasma ACE levels, with DD genotype carriers independently associated
to higher expression [45], albeit no effect was noted on AngII [45]. Thus, it seems unlikely this SNP
might impact the ACE/AngII/ATR1 axis, which has been associated with tumour cell growth and
angiogenesis, partially justifying the absence of clinical impact in NSCLC patients with advanced
stage disease. There are other possible reasons for the failure to replicate the prior findings. Many of
the initial reports were present only in retrospectively defined subsets of the subjects studied and the
main hypotheses investigated were related to cancer risk. Another possibility is that varied ethnic
background of study populations may result in a different genetic background which confers a different
biologic significance to a given functional polymorphism.
ACE2 is responsible for converting AngII to Ang-(1-7), an agonist of Mas receptor (MasR). In a
mouse lung xenograft model, it was previously shown that ACE2 overexpression inhibited both lung
cancer cell proliferation In vitro and reduced tumour growth in vivo [46]. The ACE2 rs908004 is an
intronic variant at the X-linked ACE2 gene [47]. Findings from the discovery cohort revealed that
ACE2 rs908004 heterozygous carriers presented shorter time-to-progression, only in the subgroup of
patients treated with first line platinum-based chemotherapy without actionable driver mutations.
We hypothesize that heterozygous produces reduced levels of ACE2, contributing to the up-regulation
of ACE/Ang II/AT1 receptor axis, or to linkage with another genomic region that might be relevant
for this clinical phenotype. These hypotheses need to be confirmed in further studies. Furthermore,
as with all gene association studies, subgroup analyses can lead to spurious associations and might
justify our result. Nevertheless, there is lack of studies on genotype–phenotype relationship with this
SNP in lung cancer, opening new opportunities for further investigations.
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Ang-(1-7) has opposite effects to Ang II upon binding to MasR and might be produced through
hydroxylation of Ang I by neprilysin (NEP), an enzyme encoded by the gene MME [48]. NEP,
also called CD10, has been described as a tumour-specific antigen for lymphocytic leukemia [49].
In the later years, it was demonstrated that NEP functions are implicated in oncogenesis and tumour
microenvironment [49]. Moreover, alterations in NEP protein expression have also been reported in solid
tumours, including lung cancer [50]. Both in discovery and validation cohorts, NSCLC subjects carrying
the heterozygous TC genotype were at decreased risk for disease progression, albeit in the discovery
set the protection was conferred to carriers of the TC/CC combined genotypes (dominant model),
whereas in the validation cohort it was conferred only to TC (heterosis model). Heterosis for a single
gene refers to a heterozygote that has a different phenotypic trait than for either allele homozygotes [51],
and heterozygosity has been associated with human healthy aging [52]. Despite insufficient knowledge
on the molecular basis of heterosis, an accepted mechanism is related to environmentally-driven
epigenetic modifications, namely methylation and microRNAs (miRNAs) [53]. MicroRNAs regulate
gene expression by binding to target sequences mostly at the 3’-UTR of mRNAs, and evidence exist for
their functional effect in candidate SNPs of various types of cancer [54]. Noteworthy, recently reported
data demonstrated such a mechanism with functional repercussion, the SNP rs6665, located downstream
of rs701109 in the 3’-UTR region sequence of MME [55].
We conducted an in-silico proof-of-principle analysis using the MicroSNiPer database [56,57]
to predict MME rs701109 SNP effects on putative microRNA targets, followed by study of the
candidate miRNAs using the RNAhybrid program [58,59] to calculate the minimum free energy
(MFE) of hybridization between miRNAs and target sequence (3′-UTR sequence of MME extracted
from Ensembl [37]. The strongest binding affinity was found for hsa-miR-362-3p, which overlaps the
locus of rs701109 at 3′-UTR region. A stronger predicted paring affinity between the hsa-miR-362-3p
miRNA and the target mRNA of MME was observed for C-allele (−26.1 kcal/mol) in comparison to
T-allele (−23.2 kcal/mol), stronger interaction with the miR-362-3p, resulting in lower expression of
MME, and consecutively decreased risk for disease progression. Notably, previous data confirmed
that hsa-miR-362-3p is expressed in lung tissue, aberrantly expressed in lung adenocarcinoma, and a
promoter of metastasis [60] The differences among cohorts, particularly due to distinct therapeutics,
genotype distribution and environmental stimuli, might account for different epigenetic regulation.
Experimental studies in lung cancer tissues and In vitro with lung cancer organoids are warranted to
further validate current findings.
The MME rs701109 variant consists in a nucleotide substitution of T-by-C, that has been
shown to associate with lower NEP protein expression in the brain of patients with Alzheimer’s
disease [61]. Notably, previous studies revealed that higher NEP expression associated with poorer
prognosis in NSCLC and that tumour NEP was an independent predictor of recurrence in lung
adenocarcinomas [50,62]. Taking into consideration that increased NEP expression in lung tumours
associates with worst prognosis, and that TC and CC genotype carriers secrete less protein, our findings
showing an independent protection for disease progression in TC carriers likely reflect the influence of
this SNP in decreasing NEP availability. This result strengthens the involvement of NEP in NSCLC and
supports the putative interest of including this genetic biomarker in a multilocus model for predicting
relapse. Nevertheless, despite the known ability of NEP to degrade mitogenic peptides, the lack of
Ang II degradation, as well as reduced production of Ang-(1-7) by NEP, might account for the growth
of lung cancer cells [15]. Taken together, accumulated data and current findings support the need to
foster research in neprilysin actions on cancer, particularly in lung cancer.
Hypoxia is a hallmark of solid tumours, and consequently related to enhanced aggressiveness,
risk of disease progression and therapy resistance, effects known to be largely mediated by
hypoxia-inducible factors [63]. The downstream upregulated vascular endothelial growth factor
(VEGF) further contributes to cancer growth and metastasis, directly targeting tumour cells. Increased
VEGF expression and/or circulating VEGF levels have been consistently reported in lung cancer [64].
Noteworthy, the activation of RAS in the tumour microenvironment usually involves Ang II, which has
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been described to induce hypoxia through reactive oxygen species production, and subsequent
activation of pro-inflammatory and pro-angiogenic signals [65]. Albeit no clinical impact was
demonstrated for polymorphisms in HIFA, PGF and FLT1 genes, associations were observed in the
discovery set for VEGFA rs25648 with PFS (univariate analysis) and KDR rs1870377 with PFS and OS
(multivariate analysis). Koukourakis et al. [66], described that inherited VEGF sequence variations
were strong determinants of the molecular VEGF and VEGF-downstream phenotype of NSCLC,
being the substitution C > A at locus −2578 associated with higher levels of VEGF. Another study
showed that VEGFA rs25648 (−73C > T) was a prognostic biomarker for PFS and OS in patients
with hepatocellular carcinoma, with C-allele conferring improved prognosis, despite not confirmed
in multivariate analysis [67]. In the discovery cohort, lung cancer patients had a different outcome
since the homozygous C for VEGF rs25648 had lower time until disease progression in univariate
analysis. The apparently conflicting results might be due to particularities related with different
cancer models. Notably, studies investigating the potential association between VEGF polymorphisms
and circulating VEGF levels also led to controversial results [68–70], opening new opportunities for
further investigations to clarify the role of germline VEGF variations in NSCLC progression and its
repercussion in VEGF levels.
The KDR rs1870377 was significantly associated with PFS and OS in the discovery set. Homozygous
T and C had increased risk for tumour progression PFS and death, independent of clinicopathological
variables and after bootstrap analysis. Findings were not replicated in the validation cohort.
KDR encodes VEGFR-2, the key receptor mediating endothelial cell proliferation and sprouting,
leading to angiogenesis and tumour promotion upon binding and signalling through the VEGFA
pathway [71]. The KDR rs1870377 (c.1719A > T) variant induces a missense alteration in exon 11 that
results in the substitution A > T and in the amino acid modification Gln472His. This substitution was
previously described to alter the function of VEGF-KDR signalling pathway, enhancing ligand/receptor
binding efficacy and upregulated signal transduction, ultimately leading to increased microvessel
density [72]. This phenotypic correlation with the KDR rs1870377 might support T homozygous
findings, hypothetically by promoting tumour vascular density for homozygous carriers. Previous
findings reported that microvessel count, reflecting tumour neoangiogenesis, appeared to be a poor
prognostic factor for survival in NSCLC patients [73], despite some conflicting results [74].
This study provides evidence that SNPs coding for molecules involved in the RAS (ACE2 rs908004,
MME rs701109, KDR rs1870377) might influence PFS and OS in advanced NSCLC patients, although only
MME rs701109 was validated in an independent cohort. Candidate SNP studies searching
associations with clinically relevant endpoints, have been reported to yield false-positive findings. Here,
the multivariate model was first developed in a cohort of consecutively recruited advanced NSCLC
patients. Furthermore, we included a robust data analyses setting that included: (i) sample size and
number of events in both cohorts were within adequated estimations, (ii) initial empirical analyses to
include only the most relevant variables in the multivariate models, (iii) bootstrapping using Montecarlo
simulations with 1000 iterations to strengthen internal validation in each cohort, and (iv) validation of
important SNPs from the discovery set in an independent cohort of lung cancer patients matched for
demographic and pathological characteristics. Nevertheless, despite matching for clinicopathological
characteristics, differences between discovery and validation cohorts existed, and this could partially
explain the validation of a single polymorphism. Particularly, the validation set was selected from a
larger lung cancer database and somatic mutational analyses were determined using distinct methods,
revealing different mutational status for both cohorts, which likely influenced the course of disease and
the subsequent therapeutic decisions. In addition, differences in respiratory co-morbidities, which may
have conducted to mismatched treatment modalities (surgery with adjuvant chemotherapy versus
chemo with radiotherapy for stages IIIA–IIIB), combined with the genetic background may also add to
explain failure to validate the other genetic polymorphisms.
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5. Conclusions
Germline genetic variants are common genomic events, putatively inducing phenotypic
modifications affecting both normal physiology and cancer physiopathology. Data presented here
supports the rationale for NEP and RAS mechanistic involvement in NSCLC, whereas the polymorphism
MME rs701109 might prove to be a useful biomarker for NSCLC progression. These findings
will foster further and larger studies to confirm the role of RAS, and particularly NEP in NSCLC,
as well as to determine the usefulness of MME rs701109 as a molecular marker for disease progression.
Taken together, these results can lead to a better understanding of NEP influence in the NSCLC
biological mechanisms, contributing towards the definition of a genetic profile for this disease and
eventually serve as guidance for therapeutic decisions.
Supplementary Materials: The following are available online at http://www.mdpi.com/2072-6694/12/12/3834/s1,
Table S1: Representative single nucleotide polymorphisms (SNPs) of genes involved in RAS (ACE, ACE2,
AGT, AGTR1, AGTR2, MME, CMA1, MAS1) and SNPs of genes that express hypoxia-inducible factor
1-alpha, hypoxia-inducible factor 1-beta, hypoxia-inducible factor 2-alpha, hypoxia-inducible factor 2-beta,
vascular endothelial growth factor and its receptor, placental growth factor and its receptor, Table S2.
Clinical-pathological variables and progression-free survival (PFS) and overall survival (OS) in discovery
set (n = 167)—Univariate analysis, Table S3: Discovery Set (n = 167): progression-free survival (PFS) and
overall survival (OS)—Univariate analysis, Table S4. Clinical-pathological variables and progression-free survival
(PFS) and overall survival (OS) in validation set (n = 190)—Univariate analysis, Table S5. Validation Set
(n = 190)—Univariate analysis.
Author Contributions: Conceptualization, M.J.C., R.M. and R.R.; Data curation, M.J.C., A.P., J.G.F. and T.M.;
Formal analysis, M.J.C., J.G.F., M.F.M., M.T., M.K., M.M., M.A.S., T.M. and R.R.; Funding acquisition, M.J.C. and
C.R.C.; Investigation, M.J.C., C.R.C., F.J.F.H., M.T., M.M. and R.R.; Methodology, M.J.C., M.K., M.M., T.M. and
R.R.; Project administration, M.A.S. and T.M.; Resources, M.J.O., A.P., J.G.F., M.F.M., F.J.F.H., M.K., M.M., M.A.S.
and T.M.; Supervision, R.M., M.J.O., C.R.C., M.M., T.M. and R.R.; Validation, T.M.; Writing—original draft, M.J.C.;
Writing—review & editing, M.J.O., T.M. and R.R. All authors have read and agreed to the published version of
the manuscript.
Funding: M.J.C. was supported by the Associação de Estudos Respiratórios and the Portuguese
Pulmonology Society.
Acknowledgments: M.J.C. would like to dedicate this work in the lovely memory of Maria João Matos, eminent
senior pulmonologist, who was a continuous support and inspiration throughout this study and during her
Pulmonology residency. Authors acknowledge Margarida Lourenço and technical support from Elisabete Camilo,
Isabel Marques and Andreia Coelho in DNA extraction. Authors also acknowledge to Liz Meister and Martin
Fallenbüchel for technical assistance and Maria Torres for genotyping using MASS ARRAY iPLEX Gold.
Conflicts of Interest: All authors declare that they have no conflict of interest.
References
1. Ferlay, J.; Colombet, M.; Soerjomataram, I.; Mathers, C.; Parkin, D.M.; Piñeros, M.; Znaor, A.; Bray, F. Estimating
the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods. Int. J. Cancer 2019,
144, 1941–1953. [CrossRef]
2. Lavoie, J.L.; Sigmund, C.D. Minireview: Overview of the Renin-Angiotensin System—An Endocrine and
Paracrine System. Endocrinology 2003, 144, 2179–2183. [CrossRef]
3. Wegman-Ostrosky, T.; Soto-Reyes, E.; Vidal-Millán, S.; Sánchez-Corona, J. The renin-angiotensin system
meets the hallmarks of cancer. J. Renin-Angiotensin-Aldosterone Syst. 2015, 16, 227–233. [CrossRef]
4. Catarata, M.J.P.; Ribeiro, R.; Oliveira, M.J.; Robalo-Cordeiro, C.; Medeiros, R. Renin-Angiotensin System in
Lung Tumor and Microenvironment Interactions. Cancers 2020, 12, 1457. [CrossRef]
5. Takai, S.; Jin, D.; Miyazaki, M. New approaches to blockade of the renin-angiotensin-aldosterone system:
Chymase as an important target to prevent organ damage. J. Pharmacol. Sci. 2010, 113, 301–309. [CrossRef]
6. Jiang, Y.; Wu, Y.; Hardie, W.J.; Zhou, X. Mast cell chymase affects the proliferation and metastasis of lung
carcinoma cells in vitro. Oncol. Lett. 2017, 14, 3193–3198. [CrossRef]
7. Ferrario, C.M.; Trask, A.J.; Jessup, J.A. Advances in biochemical and functional roles of angiotensin-converting
enzyme 2 and angiotensin-(1–7) in regulation of cardiovascular function. Am. J. Physiol. Circ. Physiol. 2005,
289, H2281–H2290. [CrossRef]
Cancers 2020, 12, 3834 13 of 16
8. Papandreou, C.N.; Usmani, B.; Geng, Y.; Bogenrieder, T.; Freeman, R.; Wilk, S.; Finstad, C.L.; Reuter, V.E.;
Powell, C.T.; Scheinberg, D.; et al. Neutral endopeptidase 24.11 loss in metastatic human prostate cancer
contributes to androgen-independent progression. Nat. Med. 1998, 4, 50–57. [CrossRef]
9. Imai, N.; Hashimoto, T.; Kihara, M.; Yoshida, S.-I.; Kawana, I.; Yazawa, T.; Kitamura, H.; Umemura, S. Roles
for host and tumor angiotensin II type 1 receptor in tumor growth and tumor-associated angiogenesis.
Lab. Investig. 2006, 87, 189–198. [CrossRef]
10. Jethon, A.; Puła, B.; Piotrowska, A.; Wojnar, A.; Ryś, J.; Dzięgiel, P.; Podhorska-Okolow, M. Angiotensin II
Type 1 Receptor (AT-1R) Expression Correlates with VEGF-A and VEGF-D Expression in Invasive Ductal
Breast Cancer. Pathol. Oncol. Res. 2012, 18, 867–873. [CrossRef]
11. Lewandowska, U.; Lachowicz-Ochędalska, A.; Domińska, K.; Kaszewska, D.; Rębas, E. Angiotensin II as a
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